Despite No Current Approval of Janssen's Zytiga in Asymptomatic/Minimally Symptomatic MCRPC, 31% of Surveyed Physicians Report Decreased Use of Dendreon's Provenge Because Zytiga is Available for Later Lines of Treatment

EXTON, Pa.--(BUSINESS WIRE)--

BioTrends Research Group, LLC has released findings from the LaunchTrends^®: Zytiga report, the first in a three-wave series. The study was conducted with 106 U.S. urologists and medical oncologists about their perceptions and use of Zytiga in metastatic castrate-resistant prostate cancer (MCRPC).

The FDA-approved indication for Zytiga in docetaxel-treated MCRPC patients means that more surveyed oncologists than urologists have prescribed Zytiga. The majority of medical oncologists have prescribed Zytiga compared with less than a quarter of surveyed urologists. Oncologists typically manage the treatment of symptomatic MCRPC patients at the point at which chemotherapy is initiated, but urologists manage hormonal therapies in earlier lines of prostate cancer treatment. Surveyed urologists and oncologists agree that urologists now have a greater role in the treatment of MCRPC as a result of the launch of the novel hormonal therapy, Zytiga. However, urologists and oncologists have differing opinions about the future role of urologists in MCRPC treatment.

The majority of current Zytiga prescribers are satisfied with Zytiga's overall clinical profile, but in the docetaxel-treated MCRPC setting Jevtana poses considerable competition to the growth of Zytiga. However, the majority of surveyed oncologists and urologists consider Zytiga to be favorable over Jevtana. In various different docetaxel-treated MCRPC patient sub-populations, Zytiga has already captured greatest patient share out of any currently available therapy according to surveyed urologists and oncologists in the United States. While uptake of Zytiga is significant in the docetaxel-treated MCRPC patient population, physicians also believe use of Zytiga is appropriate in multiple other prostate cancer patient populations; however they recognize hurdles associated with gaining reimbursement of Zytiga in non-approved settings.

LaunchTrends^®: Zytiga is a series of three post-launch syndicated reports designed to track physician perception, uptake, and the competitive environment of Zytiga in MCRPC. For this first wave of research, which measures Zytiga's market impact at six months following approval, BioTrends surveyed 106 oncologists (n=55) and urologists (n=51) in the United States and conducted qualitative interviews with a subset of 20 respondents in November 2011. BioTrends evaluates the changing role of the urologist in the management of MCRPC as a result of Zytiga's launch, the threat of emerging therapies on Zytiga's continuing success, and the future for Zytiga in additional patient populations other than docetaxel-treated MCRPC. BioTrends will continue to track the uptake of Zytiga in two subsequent waves in this series throughout 2012.

About BioTrends Research Group, LLC

BioTrends Research Group, LLC provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 321-9400 or www.bio-trends.com.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.